Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Breast Neoplasms 1

Interventions

tremelimumab 4Cystoscopy 3durvalumab 2avelumab 2Paclitaxel 2Gemcitabine 2Docetaxel 2Cisplatin 2vocimagene amiretrorepvec 1vinflunine 1trebananib 1trastuzumab duocarmazine 1pegfilgrastim 1merphos 1infigratinib 1erdafitinib 1efineptakin alfa 1copanlisib 1atezolizumab 1Vinblastine 1Trastuzumab 1Taxes 1TAS-116 1Specimen Handling 1Sirolimus 1Rosiglitazone 1Ropivacaine 1Rogaratinib 1Radiotherapy 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Urinary Bladder Neoplasms × pegfilgrastim × Clear all
NCT01639521 2014-01-29

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

University of Southern California

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡